Guangdong Jiaying Pharmaceutical Co Ltd (002198) - Net Assets
Based on the latest financial reports, Guangdong Jiaying Pharmaceutical Co Ltd (002198) has net assets worth CN¥730.39 Million CNY (≈ $106.88 Million USD) as of March 2026. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (CN¥892.78 Million ≈ $130.64 Million USD) and total liabilities (CN¥162.39 Million ≈ $23.76 Million USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check Guangdong Jiaying Pharmaceutical Co Ltd (002198) tangible equity ratio to evaluate the tangible quality of the company's equity base.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | CN¥730.39 Million |
| % of Total Assets | 81.81% |
| Annual Growth Rate | 13.64% |
| 5-Year Change | 4.89% |
| 10-Year Change | -27.1% |
| Growth Volatility | 51.42 |
Guangdong Jiaying Pharmaceutical Co Ltd - Net Assets Trend (2004–2025)
This chart illustrates how Guangdong Jiaying Pharmaceutical Co Ltd's net assets have evolved over time, based on quarterly financial data. See Guangdong Jiaying Pharmaceutical Co Ltd (002198) liquidity interval to measure how many days the company can operate on defensive assets alone.
Annual Net Assets for Guangdong Jiaying Pharmaceutical Co Ltd (2004–2025)
The table below shows the annual net assets of Guangdong Jiaying Pharmaceutical Co Ltd from 2004 to 2025. For live valuation and market cap data, see Guangdong Jiaying Pharmaceutical Co Ltd (002198) total market value.
| Year | Net Assets | Change |
|---|---|---|
| 2025-12-31 | CN¥717.93 Million ≈ $105.06 Million |
-5.31% |
| 2024-12-31 | CN¥758.22 Million ≈ $110.95 Million |
-0.62% |
| 2023-12-31 | CN¥762.98 Million ≈ $111.65 Million |
+4.75% |
| 2022-12-31 | CN¥728.42 Million ≈ $106.59 Million |
+6.42% |
| 2021-12-31 | CN¥684.48 Million ≈ $100.16 Million |
+0.22% |
| 2020-12-31 | CN¥683.01 Million ≈ $99.95 Million |
+2.99% |
| 2019-12-31 | CN¥663.17 Million ≈ $97.04 Million |
-15.56% |
| 2018-12-31 | CN¥785.35 Million ≈ $114.92 Million |
+4.74% |
| 2017-12-31 | CN¥749.81 Million ≈ $109.72 Million |
-23.87% |
| 2016-12-31 | CN¥984.87 Million ≈ $144.12 Million |
+5.93% |
| 2015-12-31 | CN¥929.70 Million ≈ $136.04 Million |
+7.69% |
| 2014-12-31 | CN¥863.35 Million ≈ $126.33 Million |
+6.63% |
| 2013-12-31 | CN¥809.66 Million ≈ $118.48 Million |
+191.16% |
| 2012-12-31 | CN¥278.08 Million ≈ $40.69 Million |
+2.80% |
| 2011-12-31 | CN¥270.51 Million ≈ $39.58 Million |
+4.66% |
| 2010-12-31 | CN¥258.47 Million ≈ $37.82 Million |
+7.06% |
| 2009-12-31 | CN¥241.42 Million ≈ $35.33 Million |
+6.66% |
| 2008-12-31 | CN¥226.35 Million ≈ $33.12 Million |
+6.45% |
| 2007-12-31 | CN¥212.62 Million ≈ $31.11 Million |
+157.33% |
| 2006-12-31 | CN¥82.63 Million ≈ $12.09 Million |
+28.32% |
| 2005-12-31 | CN¥64.39 Million ≈ $9.42 Million |
+31.49% |
| 2004-12-31 | CN¥48.97 Million ≈ $7.17 Million |
-- |
Equity Component Analysis
This analysis shows how different components contribute to Guangdong Jiaying Pharmaceutical Co Ltd's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have grown by 4277.5% over the analyzed period, indicating profitable operations and earnings retention.
Current Equity Component Breakdown (December 2025)
| Component | Amount | Percentage |
|---|---|---|
| Retained Earnings | CN¥129.50 Million | 18.04% |
| Other Components | CN¥588.43 Million | 81.96% |
| Total Equity | CN¥717.93 Million | 100.00% |
Guangdong Jiaying Pharmaceutical Co Ltd Competitors by Market Cap
The table below lists competitors of Guangdong Jiaying Pharmaceutical Co Ltd ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Dolly Varden Silver Corporation
V:DV
|
$247.57 Million |
|
MFS Charter Income Trust
NYSE:MCR
|
$247.63 Million |
|
Samsung C and T 1P Pref
KO:02826K
|
$247.65 Million |
|
MTM Critical Metals Ltd
AU:MTM
|
$247.65 Million |
|
Rithm Acquisition Corp.
NYSE:RAC
|
$247.25 Million |
|
Honest Company Inc
NASDAQ:HNST
|
$247.06 Million |
|
Fossil Group Inc
NASDAQ:FOSL
|
$247.04 Million |
|
Launch One Acquisition Corp. Unit
NASDAQ:LPAAU
|
$247.02 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Guangdong Jiaying Pharmaceutical Co Ltd's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 758,220,755 to 717,929,630, a change of -40,291,125 (-5.3%).
- Net income of 30,477,433 contributed positively to equity growth.
- Other comprehensive income decreased equity by 27,767,450.
- Other factors decreased equity by 43,001,108.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | CN¥30.48 Million | +4.25% |
| Other Comprehensive Income | CN¥-27.77 Million | -3.87% |
| Other Changes | CN¥-43.00 Million | -5.99% |
| Total Change | CN¥- | -5.31% |
Book Value vs Market Value Analysis
This analysis compares Guangdong Jiaying Pharmaceutical Co Ltd's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 2.35x
- The company is trading above its book value, indicating the market recognizes value beyond its reported assets.
- The price-to-book ratio has decreased from 18.83x to 2.35x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2004-12-31 | CN¥0.18 | CN¥3.33 | x |
| 2005-12-31 | CN¥0.21 | CN¥3.33 | x |
| 2006-12-31 | CN¥0.27 | CN¥3.33 | x |
| 2007-12-31 | CN¥0.70 | CN¥3.33 | x |
| 2008-12-31 | CN¥0.56 | CN¥3.33 | x |
| 2009-12-31 | CN¥0.58 | CN¥3.33 | x |
| 2010-12-31 | CN¥0.63 | CN¥3.33 | x |
| 2011-12-31 | CN¥0.66 | CN¥3.33 | x |
| 2012-12-31 | CN¥0.68 | CN¥3.33 | x |
| 2013-12-31 | CN¥1.90 | CN¥3.33 | x |
| 2014-12-31 | CN¥1.70 | CN¥3.33 | x |
| 2015-12-31 | CN¥1.83 | CN¥3.33 | x |
| 2016-12-31 | CN¥1.94 | CN¥3.33 | x |
| 2017-12-31 | CN¥1.48 | CN¥3.33 | x |
| 2018-12-31 | CN¥1.55 | CN¥3.33 | x |
| 2019-12-31 | CN¥1.31 | CN¥3.33 | x |
| 2020-12-31 | CN¥1.35 | CN¥3.33 | x |
| 2021-12-31 | CN¥1.34 | CN¥3.33 | x |
| 2022-12-31 | CN¥1.44 | CN¥3.33 | x |
| 2023-12-31 | CN¥1.50 | CN¥3.33 | x |
| 2024-12-31 | CN¥1.49 | CN¥3.33 | x |
| 2025-12-31 | CN¥1.41 | CN¥3.33 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Guangdong Jiaying Pharmaceutical Co Ltd utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 4.25%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 7.94%
- • Asset Turnover: 0.45x
- • Equity Multiplier: 1.18x
- Recent ROE (4.25%) is below the historical average (5.31%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2004 | 5.65% | 7.39% | 0.52x | 1.47x | CN¥-2.13 Million |
| 2005 | 23.95% | 28.37% | 0.60x | 1.42x | CN¥8.98 Million |
| 2006 | 26.76% | 35.28% | 0.52x | 1.45x | CN¥13.85 Million |
| 2007 | 11.48% | 37.81% | 0.26x | 1.15x | CN¥3.16 Million |
| 2008 | 6.06% | 20.68% | 0.28x | 1.04x | CN¥-8.91 Million |
| 2009 | 6.25% | 24.19% | 0.25x | 1.05x | CN¥-9.06 Million |
| 2010 | 9.77% | 33.55% | 0.25x | 1.16x | CN¥-600.14K |
| 2011 | 7.48% | 23.56% | 0.28x | 1.13x | CN¥-6.81 Million |
| 2012 | 2.72% | 7.24% | 0.33x | 1.13x | CN¥-20.24 Million |
| 2013 | 17.23% | 61.52% | 0.25x | 1.14x | CN¥58.52 Million |
| 2014 | 8.53% | 13.02% | 0.55x | 1.20x | CN¥-12.68 Million |
| 2015 | 7.14% | 13.95% | 0.45x | 1.13x | CN¥-26.62 Million |
| 2016 | 5.60% | 12.26% | 0.41x | 1.12x | CN¥-43.32 Million |
| 2017 | -28.64% | -45.88% | 0.53x | 1.17x | CN¥-289.74 Million |
| 2018 | 4.57% | 6.68% | 0.60x | 1.13x | CN¥-42.66 Million |
| 2019 | -18.42% | -24.41% | 0.58x | 1.29x | CN¥-188.50 Million |
| 2020 | 2.90% | 3.64% | 0.67x | 1.18x | CN¥-48.46 Million |
| 2021 | 0.22% | 0.26% | 0.71x | 1.18x | CN¥-66.97 Million |
| 2022 | 6.03% | 6.66% | 0.78x | 1.16x | CN¥-28.91 Million |
| 2023 | 4.50% | 6.44% | 0.63x | 1.11x | CN¥-41.98 Million |
| 2024 | 2.72% | 5.48% | 0.45x | 1.11x | CN¥-55.21 Million |
| 2025 | 4.25% | 7.94% | 0.45x | 1.18x | CN¥-41.32 Million |
Industry Comparison
This section compares Guangdong Jiaying Pharmaceutical Co Ltd's net assets metrics with peer companies in the Drug Manufacturers - General industry.
Industry Context
- Industry: Drug Manufacturers - General
- Average net assets among peers: $5,350,832,212
- Average return on equity (ROE) among peers: 7.37%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Guangdong Jiaying Pharmaceutical Co Ltd (002198) | CN¥730.39 Million | 5.65% | 0.22x | $247.30 Million |
| Zhejiang Int'L Group Co Ltd (000411) | $3.21 Billion | 10.69% | 2.51x | $732.38 Million |
| Zhejiang Zhenyuan Share Co Ltd (000705) | $1.98 Billion | 1.15% | 0.48x | $308.51 Million |
| Hunan Jingfeng Pharmaceutical (000908) | $-153.68 Million | 0.00% | 0.00x | $750.55 Million |
| Hubei Guangji Pharmaceutical Co Ltd (000952) | $134.18 Million | 12.98% | 0.83x | $302.41 Million |
| Yifan Xinfu Pharmaceutical Co Ltd (002019) | $9.15 Billion | 2.09% | 0.37x | $1.73 Billion |
| Sichuan Kelun Pharmaceutical Co Ltd (002422) | $29.29 Billion | 5.81% | 0.36x | $8.36 Billion |
| Chongqing Lummy Pharmaceutical (300006) | $1.65 Billion | -9.38% | 1.12x | $760.20 Million |
| Zhejiang Jolly Pharmaceutical Co Ltd (300181) | $2.77 Billion | 13.80% | 0.31x | $1.32 Billion |
| Zhejiang Wolwo Bio-Pharmaceutical Co Ltd (300357) | $127.61 Million | 29.20% | 0.15x | $1.63 Billion |
About Guangdong Jiaying Pharmaceutical Co Ltd
Guangdong Jiaying Pharmaceutical Co., Ltd. engages in the research and development, production, and sale of Chinese patent medicines in Mainland China. The company offers medicines primarily for the treatment of throat, cold, orthopedics, rheumatism, gynecology, heat-clearing, tonic, and gastrointestinal diseases. It also provides Shuangliao Houfeng powder, Chongganling tablets, Jiegu Qili tablet… Read more